drugset / Trial / NCT02229747

Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis

NCT02229747

Phase 4 Completed 128 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study was to assess the clinical efficacy and safety of meloxicam suspension 0.25 mg/kg/day once a day, versus diclofenac suspension 1 mg/kg/day twice a day or nimesulide suspension 4 mg/kg/day twice a day, after five days of treatment in patients with a diagnosis of acute, non-bacterial pharyngitis, pharyngotonsillitis or laryngitis

Timeline

Start
2001-08
Primary completion
2002-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diclofenac Other / unclassified 1 mg/kg
Subject Meloxicam Small molecule 0.25 mg/kg
Comparator Nimesulide Small molecule 4 mg/kg

Indications